MINNEAPOLIS--(BUSINESS WIRE)--Nov. 26, 2012-- Piper Jaffray (NYSE: PJC) today announced that Jeff Ammerman joined as a principal in the healthcare investment banking group. Ammerman will lead coverage of the specialty pharmaceuticals universe and be based in San Francisco.
“We are excited to have Jeff join our team,” commented Chad Abraham, global co-head of investment banking and capital markets at Piper Jaffray. “Healthcare is a strategically critical industry for our firm and we have a highly ranked advisory and equities business. The specialty pharmaceutical universe has been a target area for us and matches up well with our existing coverage. Also, expanding our healthcare reach to San Francisco demonstrates our long-term commitment to the Piper Jaffray healthcare franchise.”
Bob DeSutter, global head of healthcare investment banking added, “Our healthcare group is a market-leading platform, serving emerging growth and established clients broadly across life sciences and healthcare services. Jeff’s experience serving clients with advisory as well as the full suite of capital market products provides a great fit with our platform.”
Ammerman brings over 12 years of healthcare investment banking experience to Piper Jaffray. He joins the firm from Jefferies, where he was a senior calling officer in the global healthcare group. Over the last six years with Jefferies, Ammerman was instrumental in building the healthcare team, both domestically and internationally, and served as a founding member of the international healthcare group in London.
Piper Jaffray has a global healthcare investment banking and capital markets team of 45. Since 2007, the team has represented clients in 191 transactions with an aggregate value of $32 billion. In addition, the firm has nine senior research analysts, covering a broad spectrum of universes, including medical technology, drug discovery, medical diagnostics, life science tools, specialty pharmaceuticals, biotechnology, and healthcare services, including information technology, alternate site providers and contract research.
“We are excited to have Jeff join our team,” commented Chad Abraham, global co-head of investment banking and capital markets at Piper Jaffray. “Healthcare is a strategically critical industry for our firm and we have a highly ranked advisory and equities business. The specialty pharmaceutical universe has been a target area for us and matches up well with our existing coverage. Also, expanding our healthcare reach to San Francisco demonstrates our long-term commitment to the Piper Jaffray healthcare franchise.”
Bob DeSutter, global head of healthcare investment banking added, “Our healthcare group is a market-leading platform, serving emerging growth and established clients broadly across life sciences and healthcare services. Jeff’s experience serving clients with advisory as well as the full suite of capital market products provides a great fit with our platform.”
Ammerman brings over 12 years of healthcare investment banking experience to Piper Jaffray. He joins the firm from Jefferies, where he was a senior calling officer in the global healthcare group. Over the last six years with Jefferies, Ammerman was instrumental in building the healthcare team, both domestically and internationally, and served as a founding member of the international healthcare group in London.
Piper Jaffray has a global healthcare investment banking and capital markets team of 45. Since 2007, the team has represented clients in 191 transactions with an aggregate value of $32 billion. In addition, the firm has nine senior research analysts, covering a broad spectrum of universes, including medical technology, drug discovery, medical diagnostics, life science tools, specialty pharmaceuticals, biotechnology, and healthcare services, including information technology, alternate site providers and contract research.
